Clinical trial
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in…
NCT02831855 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT02831855 |
|---|---|
| Title | Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis |
| Official title | A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | CP-690, 550, Methotrexate, Placebo |
| Enrollment | 694 |
| Start date | Sep 1, 2016 |
| Primary completion | Nov 19, 2018 |
| Completion | Dec 17, 2018 |
| First posted | Jul 13, 2016 |
| Last update posted | Dec 4, 2019 |
| Countries | Australia, Belgium, Bulgaria, Czechia, Germany, Hungary, Mexico, Philippines, Poland, Russia, Slovakia, South Africa and 4 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: